Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Tazemetostat

Inh 1403254-99-8 N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide
Catalog No. ABIN7233296
  • Application
    Inhibition (Inh)
    Purpose
    EZH2 inhibitor
    Characteristics
    Potent and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2 (Ki = 2.5nM wild type human PRC2-containing). Displayed strong antiproliferative effects against SMARCB1-deleted malignant rhabdoid tumor (MRT) cell lines in vitro. Antitumor activity was also observed in SMARTCB1 mutant mouse xenografts. Displays potent antitumor activity in various cancer models including non-Hodgkins lymphoma, pediatric glioma, small-cell carcinoma of the ovary, and synovial sarcomas. Tazemetostat has also been shown to control inflammatory genes by modulating IRF1, IRF8, and STAT1 levels suggesting therapeutic potential for the treatment of neuroinflammatory diseases associated with microglial activation.
    Purity
    >98 %
    Chemical Name
    N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide
    Formula
    C34H44N4O4
    Solubility
    Soluble in DMSO (up to at least 25 mg/ml)
  • Restrictions
    For Research Use only
  • Format
    Powder
    Storage
    -20 °C
  • Background
    EPZ-6438,Transcription,Epigenetics,Proliferation,Protein methyltransferase,Cancer stem cells,Inflammation,Cancer,Posttranslational modification,Neurodegeneration,Chromatin
    Molecular Weight
    572.75
    CAS-No
    1403254-99-8
You are here:
Support